EIR Brochure Final 2 Paperturn - Flipbook - Page 6
CASE STUDY: CURIAL
CURIAL is a clinically-validated Artificial Intelligence tool which
screens patients attending hospital Emergency Departments (ED) for
COVID-19. CURIAL uses routine data (already collected within the
first hour of patients coming to hospital) and readily integrates into
today’s clinical workflows and electronic health record systems
(eHRS). The CURIAL algorithm evaluates these data to provide a highconfidence test of exclusion for COVID-19 within a patient's first
hour in the hospital. In a recent pilot at the John Radcliffe, CURIAL
was deployed alongside a point-of-care device to achieve COVID-19
screening in just 10 minutes. When compared to lateral flow testing,
CURIAL demonstrated a 26% reduction in time-to-result from a
patient arriving at the ED, and was 21% more effective at identifying
patients with COVID-19.
CURRENT DEVELOPMENTAL STAGE:
CURIAL has undergone multicentre evaluation across 4 NHS trusts in
over 72,000 patients. CURIAL has been deployed in a pilot at the John
Radcliffe Hospital's Emergency Department.
SUPPORT OFFERED THROUGH THE EXPERTS IN RESIDENCE
PROGRAMME:
Initially funded through the Medical and Life Sciences Translational
Fund MLSTF scheme, the project underwent a ‘surgery session’ to
discuss progress and long-term translation strategy with key
members of the ExIR programme, Dr Nessa Carey and Dr Jan Wolber
(Global Product Leader at GE Healthcare).
The ExIR scheme provides exposure to expertise that would
otherwise be very difficult to obtain, from a range of
personalities who seem highly supportive and well-informed.
Professor David Clifton
Professor of Clinical Machine Learning
Curial
KEY OUTPUTS HAVE INCLUDED:
Advice on strategy model and licensing for national and international
adoption of the technology into clinical settings. Identification of
potential downstream partnering companies and investors to exploit
multiple major global market entry (US and UK), in parallel. Exploitation
of the Experts’ wider network to co-ordinate connections with key
investors and partnering companies. Recommendation to work with a
third party market analysis company to gather detailed information on
market awareness, competition analysis and rapid route to
implementation information.
Subsequent meetings with further ExIRs were recommended following
the surgery session:
Dr Steven Haken (Odelle Technology): Steven identified and
connected the researchers to key healthcare digital automation
companies to understand adoption processes and to explore
collaborative opportunities.
Ben Wensley-Stock (Wensley Stock Ltd) and Dr Toni Day
(Organox): Provided advice and knowledge on device and software
classification and clarity on intended use. Guidance on process and
evidence required to seek regulatory approval was provided; the
'emergency use authorization' regulatory processes were explored
given the timely need during the pandemic.
WHERE IS THE TECHNOLOGY NOW?
The CURIAL team are in discussion with commercial, strategic and
innovation partners with an ambition of rapidly scaling up CURIAL to
support infection control in hospitals.
The EiR meetings have helped to bridge the leap from academic
work to a deployable, viable product...
Dr Andrew Soltan
Medical Doctor (OUH)
Curial